A review of signal pathway induced by virulent protein CagA of Helicobacter pylori

Hai‐Qiang Wang, Mei Zhao, Fan Shi, Shudan Zheng, Li Xiong, Lihong ZhengFrontiers in Cellular and Infection Microbiology 2023 · DOI

TL;DR

This review consolidates current knowledge on how the Helicobacter pylori virulence protein CagA hijacks host cell signaling pathways, leading to gastric cancer. By dissecting the roles of key pathways like MAPK, PI3K/Akt, and Wnt/β-catenin, the paper offers a comprehensive overview of CagA's oncogenic mechanisms and highlights potential therapeutic targets for H. pylori-associated gastric cancer.

What Problem Does This Paper Address?

Gastric cancer (GC) remains a significant global health challenge, and Helicobacter pylori (H. pylori) infection is a well-established major risk factor. While numerous bacterial factors contribute to H. pylori's pathogenicity, the virulence protein CagA stands out as the only bacterial oncoprotein identified to date. Understanding precisely how CagA manipulates host cellular processes to drive the development of GC is crucial for developing effective prevention and treatment strategies. This paper addresses the need for a consolidated overview of the complex signaling network dysregulated by CagA, aiming to clarify its role in gastric carcinogenesis.

Methods

This paper is a review article, meaning it synthesizes and analyzes existing research rather than presenting new experimental data. The authors systematically reviewed and compiled findings from numerous studies focusing on:

  • Structural analysis of CagA: Examining its N-terminal and C-terminal regions, including the crucial EPIYA motifs and the CagA multimerization (CM) motif, and how these structural features relate to its function.
  • Mechanism of CagA translocation and activation: Describing how CagA enters host cells (gastric epithelial cells, GECs) and how it is activated, particularly through tyrosine phosphorylation at EPIYA sites by host kinases.
  • Signaling pathway analysis: Detailing how CagA, both phosphorylated and unphosphorylated, interacts with and dysregulates key intracellular signaling pathways. This includes a deep dive into the MAPK, PI3K/Akt, NF-κB, JAK-STAT, Wnt/β-catenin, and Hippo signaling pathways.
  • Pathological outcomes: Linking the dysregulation of these signaling pathways to specific cellular changes that promote GC, such as altered morphology (e.g., the "hummingbird phenotype"), increased proliferation, impaired apoptosis, immune dysregulation, and gene mutations.

The review relies on a broad literature search and synthesis of findings from molecular biology, cell biology, and cancer research.

Datasets

Not discussed in the paper. This is a review article that synthesizes existing research and does not present new experimental data or datasets.

Key Insights and Ideas

  • CagA as a master manipulator: CagA isn't just a passive passenger; it actively hijacks and rewires multiple host cell signaling pathways, acting as a central orchestrator of oncogenic transformation.
  • Dual activation modes: CagA's oncogenic potential is exerted through both tyrosine-phosphorylated and non-phosphorylated forms, highlighting its versatility in disrupting cellular homeostasis. Phosphorylation at EPIYA motifs is key for some effects (like the hummingbird phenotype), while the CM motif is crucial for others (like interacting with PAR1b).
  • EPIYA motif variation matters: The specific types and number of EPIYA motifs (e.g., EPIYA-C vs. EPIYA-D) in CagA, which vary between East Asian and Western strains of H. pylori, influence its interaction with host kinases (like SHP2 and Csk) and can contribute to regional differences in GC incidence.
  • Interconnected signaling web: The reviewed pathways (MAPK, PI3K/Akt, NF-κB, JAK-STAT, Wnt/β-catenin, Hippo) are not isolated but intricately linked. CagA's action on one pathway often has cascading effects on others, creating a complex network that promotes cancer development.
  • Beyond direct oncogenesis: CagA's influence extends to modulating the tumor microenvironment by affecting immune responses and promoting inflammation, further contributing to GC progression.

Key Results

The paper doesn't present quantitative results in the traditional sense but rather synthesizes qualitative findings from numerous studies:

  • MAPK pathway activation: CagA strongly activates ERK and JNK pathways, promoting cell growth, differentiation, and inflammation, crucial for GC progression.
  • PI3K/Akt pathway dysregulation: CagA promotes cell survival, migration, and growth by activating PI3K/Akt, inhibiting apoptosis, and potentially mediating epithelial-mesenchymal transition (EMT).
  • NF-κB pathway induction: CagA activates NF-κB, leading to the release of inflammatory cytokines like IL-8 and promoting bacterial colonization, contributing to chronic inflammation and potential gene mutations.
  • JAK-STAT pathway modulation: CagA influences the JAK-STAT pathway, impacting immune responses and promoting the survival of cancer-susceptible cells.
  • Wnt/β-catenin pathway activation: CagA disrupts E-cadherin/β-catenin complexes, leading to β-catenin accumulation and activation of genes promoting cell proliferation, invasion, and angiogenesis.
  • Hippo pathway disruption: CagA promotes YAP/TAZ activation, driving EMT and increasing the risk of early GC.

Limitations and Future Work

Limitations:

  • Review-based: As a review, it relies on the quality and completeness of existing research. Gaps in understanding may still exist.
  • Complexity of interactions: The sheer number of interacting pathways and molecules makes a complete, linear understanding challenging. The review highlights this complexity but acknowledges that further detailed mechanistic studies are needed.

Future Work:

  • Targeted therapeutic strategies: The paper strongly suggests that targeting the key signaling pathways dysregulated by CagA (MAPK, PI3K/Akt, NF-κB, JAK-STAT, Wnt/β-catenin, Hippo) offers promising avenues for developing new strategies to prevent and treat H. pylori-associated GC.
  • Combined therapies: The authors hint at the potential of combined therapies, such as using immune drugs that inhibit JAK-STAT signaling alongside other treatments, to achieve better outcomes.
  • Further mechanistic studies: While much is known, deeper investigations into the precise molecular interactions and the interplay between different signaling cascades are still warranted.

Summary updated

Abstract

Gastric cancer (GC), a common and high-mortality disease, still occupies an important position in current cancer research, and <i>Helicobacter pylori</i> (<i>H. pylori</i>) infection as its important risk factor has been a hot and challenging research area. Among the numerous pathogenic factors of <i>H. pylori</i>, the virulence protein CagA has been widely studied as the only bacterial-derived oncoprotein. It was found that CagA entering into gastric epithelial cells (GECs) can induce the dysregulation of multiple cellular pathways such as MAPK signaling pathway, PI3K/Akt signaling pathway, NF-κB signaling pathway, Wnt/β-catenin signaling pathway, JAK-STAT signaling pathway, Hippo signaling pathway through phosphorylation and non-phosphorylation. These disordered pathways cause pathological changes in morphology, adhesion, polarity, proliferation, movement, and other processes of GECs, which eventually promotes the occurrence of GC. With the deepening of <i>H. pylori</i>-related research, the research on CagA-induced abnormal signaling pathway has been updated and deepened to some extent, so the key signaling pathways activated by CagA are used as the main stem to sort out the pathogenesis of CagA in this paper, aiming to provide new strategies for the <i>H. pylori</i> infection and treatment of GC in the future.
BibTeX
@inproceedings{wang2023review,
  author = {Hai‐Qiang Wang and Mei Zhao and Fan Shi and Shudan Zheng and Li Xiong and Lihong Zheng},
  title = {{A review of signal pathway induced by virulent protein CagA of Helicobacter pylori}},
  booktitle = {Frontiers in Cellular and Infection Microbiology},
  year = {2023},
  doi = {10.3389/fcimb.2023.1062803},
}
Figure